Ondansetrom Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron works by selectively blocking serotonin (5‑HT3) receptors in the chemoreceptor trigger zone of the brain and on vagal afferent nerves in the gastrointestinal tract. This inhibition prevents serotonin‑mediated activation of the vomiting centre, thereby reducing the sensation of nausea and the act of vomiting.

The dose of Ondansetrom Kabi is determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and other individual factors. Healthcare professionals set the appropriate dosage and infusion rate according to current clinical guidelines.

Use of ondansetron during pregnancy or while breastfeeding should only be considered when the potential benefit outweighs any possible risk to the fetus or infant. Limited data are available, and clinicians typically evaluate each case individually before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, which generally provides rapid and effective control of nausea and vomiting with a favorable side‑effect profile compared with dopamine antagonists such as metoclopramide. Unlike some alternatives, ondansetron does not cause extrapyramidal symptoms, but it requires monitoring for QT prolongation, especially when combined with other QT‑affecting drugs.

Ondansetrom Kabi should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid freezing. Follow any additional handling instructions provided by the manufacturer to maintain product stability.

Ondansetrom Kabi is administered by intravenous injection. The solution is typically diluted with an appropriate compatible fluid and infused over a short period, as directed by the prescribing clinician. Administration should be performed by qualified healthcare personnel in a setting equipped for intravenous therapy.

The most serious risks include cardiac arrhythmias due to QT interval prolongation, severe allergic reactions such as anaphylaxis, and rare cases of serotonin syndrome when combined with other serotonergic agents. Patients should be monitored for any signs of these conditions, especially if they have pre‑existing cardiac disease or are taking interacting medications.

Ondansetrom Kabi is contraindicated in individuals with known hypersensitivity to ondansetron or any component of the formulation. It should also be avoided in patients receiving apomorphine, those with congenital long QT syndrome, or anyone for whom the risk of QT prolongation outweighs the therapeutic benefit.